![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MAXYGEN RECEIVES $5 MILLION FROM ROCHE
MAXYGEN RECEIVES $5 MILLION FROM ROCHE
December 14, 2005
Maxygen Inc. said Wednesday that it received a $5 million milestone from Swiss drug maker Roche Holding Ltd. in their collaboration to develop hepatitis treatments. Under a 2003 agreement, Roche licensed global rights to interferon alpha product candidates developed for hepatitis B and C. Maxygen did not specify the exact milestone that triggered the payment. Representatives from Maxygen were not available for immediate comment.
MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=AP&Date=20051214&ID=5352838)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct